Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis

被引：0
|
作者：
Jun Ho Ji
Se Hoon Park
Jeeyun Lee
Tae Won Kim
Yong Sang Hong
Kyu-pyo Kim
Sun Young Kim
Ji Yeon Baek
Hye Jin Kang
Sang Joon Shin
Byoung Yong Shim
Young Suk Park
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center
[2] University of Ulsan College of Medi cine,Department of Oncology, Asan Medical Center
[3] Center for Colorectal Cancer,Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital
[4] National Cancer Center,Department of Internal Medicine, Cancer Metastasis Research Centre, Yonsei Cancer Centre
[5] Korea Institute of Radiological and Medical Sciences,Medical Oncology Division, St. Vincent’s Hospital
[6] Yonsei University College of Medicine,Division of Hemato
[7] Catholic University of Korea,Oncology, Department of Medicine, Samsung Changwon Hospital
[8] Sungkyunkwan University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 72卷
关键词：
Colorectal cancer; Liver metastasis; Neoadjuvant; FOLFOX6; Cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 230
页数：7
相关论文
共 50 条
  • [1] Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis
    Ji, Jun Ho
    Park, Se Hoon
    Lee, Jeeyun
    Kim, Tae Won
    Hong, Yong Sang
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kang, Hye Jin
    Shin, Sang Joon
    Shim, Byoung Yong
    Park, Young Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 223 - 230
  • [2] A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis
    Ji, Jun Ho
    Park, Young Suk
    Lee, Jeeyun
    Kim, Tae Won
    Hong, Yong Sang
    Kim, Kyu-Pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kang, Hye Jin
    Shin, Sang Joon
    Shim, Byoung Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] MULTICENTER PHASE II STUDY OF FOLFOX6 AS NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH UNRESECTABLE LIVER-ONLY METASTASES FROM COLORECTAL CANCER IN JAPAN; ROOF STUDY
    Shibata, Y.
    Takahashi, T.
    Tojima, Y.
    Tsuboi, K.
    Sakamoto, E.
    Kunieda, K.
    Matsuoka, H.
    Suzumura, K.
    Sakamoto, J.
    Kondo, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 220 - 220
  • [4] Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study
    Takao Takahashi
    Yoshihisa Shibata
    Yuichiro Tojima
    Kenji Tsuboi
    Eiji Sakamoto
    Katsuyuki Kunieda
    Hiroshi Matsuoka
    Kazuyoshi Suzumura
    Mikinori Sato
    Tatsushi Naganuma
    Junichi Sakamoto
    Satoshi Morita
    Ken Kondo
    International Journal of Clinical Oncology, 2013, 18 : 335 - 342
  • [5] Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study
    Takahashi, Takao
    Shibata, Yoshihisa
    Tojima, Yuichiro
    Tsuboi, Kenji
    Sakamoto, Eiji
    Kunieda, Katsuyuki
    Matsuoka, Hiroshi
    Suzumura, Kazuyoshi
    Sato, Mikinori
    Naganuma, Tatsushi
    Sakamoto, Junichi
    Morita, Satoshi
    Kondo, Ken
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (02) : 335 - 342
  • [6] Phase II trial of FOLFOX6 plus Bevacizumab for patients with unresectable liver and only hepatic metastasis from colorectal cancer: A first preliminary analysis of the safety
    Depenni, R.
    Dealis, C.
    Perrone, S.
    Losi, L.
    Bertolini, F.
    Malavasi, N.
    Zironi, S.
    Luppi, G.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI46 - XI46
  • [7] Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer
    Ocean, A. J.
    O'Brien, K.
    Lee, J.
    Matthews, N.
    Holloway, S.
    Christos, P.
    Kung, T. S.
    Kaubisch, A.
    Chen, H.
    Wadler, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] RESULTS FROM THE CELIM STUDY: CETUXIMAB PLUS FOLFOX6 OR CETUXIMAB PLUS FOLFIRI AS NEOADJUVANT TREATMENT FOR NONRESECTABLE COLORECTAL CANCER LIVER METASTASES
    Koehne, C.
    Gruenberger, T.
    Bechstein, W.
    Hartmann, J.
    Lang, H.
    Lordick, F.
    Herrmann, T.
    Stoehlmacher, J.
    Frilling, A.
    Raab, H.
    Liersch, T.
    Ockert, D.
    Konopke, R.
    Weitz, J.
    Folprecht, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 23
  • [9] The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases.
    Emi, Yasunori
    Muro, Kei
    Yamanaka, Takeharu
    Katayose, Yu
    Uetake, Hiroyuki
    Sugihara, Kenichi
    Kakeji, Yoshihiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer
    Zhao, Ren
    Zhu, Jianwei
    Ji, Xiaopin
    Cai, Jianhua
    Wan, Fangjun
    Li, Qing
    Zhong, Baoliang
    Tucker, Steven
    Wang, Daoyuan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 10 - 16
12345